MAPT and Cognitive impairment: We previously developed a Qβ VLP displaying the pT181 phospho-tau epitope (Qβ-pT181) which demonstrated a robust efficacy at reducing tau pathology, rescuing cognitive deficits, reducing neuronal cell death, and attenuating microglial inflammation.